New drug combo aims to outsmart Hard-to-Treat cancers
NCT ID NCT06789172
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, stomach, or sarcoma. About 146 participants will take part across the US, Australia, UK, and EU.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OKN4395 (an experimental drug) and pembrolizumab (an immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGSydney, New South Wales, Australia
-
Churchill Hospital
RECRUITINGOxford, United Kingdom
-
Leicester Royal Infirmary
RECRUITINGLeicester, LE1 5WW, United Kingdom
-
Linear Clinical Research
RECRUITINGPerth, Western Australia, 6009, Australia
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Precision NextGen Oncology and Research Center
RECRUITINGBeverly Hills, California, 90212, United States
-
Sarcoma Oncology Center
RECRUITINGSanta Monica, California, 90403, United States
-
The Beatson
RECRUITINGGlasgow, United Kingdom
-
The Christie
RECRUITINGManchester, United Kingdom
-
University College London Hospital
RECRUITINGLondon, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a pill keep lung cancer from returning after surgery?
- Why are more younger adults getting colorectal cancer? a national study digs into the data